<DOC>
	<DOC>NCT01557647</DOC>
	<brief_summary>To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.</brief_summary>
	<brief_title>Safety and Efficacy of Inhaled Treprostinil in Patients With PAH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Eligible subjects must: Be between 18 and 75 years of age at Screening (as defined by date of informed consent is signed), Have a diagnosis of idiopathic or heritable PAH, PAH associated with connective tissue disease (CTD), PAH associated with repaired congenital systemictopulmonary shunts (at least 1 year since repair) or human immunodeficiency virus (HIV) infection, or PAH associated with appetite suppressant or toxin use. Be treatment na√Øve, or receiving background PAH therapies (e.g., phosphodiesterase type5 inhibitor (PDE5i)and / or endothelin receptor antagonist (ERA)) for less than 1 year prior to Screening. Have a 6MWD at Baseline (as measured by the mean value of two 6MWT separated by at least 24 hours, but no more than 14 days) that is between 150 500 meters, inclusive.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>